The implantable drug delivery devices market size has grown strongly in recent years. It will grow from $21.94 billion in 2025 to $23.91 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to advancements in implantable medical device design, rising prevalence of chronic diseases, increased use of long-term drug therapies, growth in minimally invasive surgical procedures, expansion of oncology and cardiovascular treatments.
The implantable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $33.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of smart implantable devices, rising demand for personalized drug delivery, expansion of biodegradable implant technologies, growing investments in combination drug-device products, increasing regulatory approvals for implantable therapies. Major trends in the forecast period include increasing adoption of controlled-release implant systems, rising use of bio-absorbable implant materials, growing demand for site-specific drug delivery, expansion of miniaturized implantable devices, enhanced focus on patient compliance.
The increasing incidence of chronic diseases is expected to drive the growth of the implantable drug delivery devices market in the coming years. Chronic diseases are long-lasting medical conditions that persist for extended periods, typically three months or more. The rise in chronic diseases is largely attributed to widespread unhealthy lifestyle habits, such as poor nutrition, physical inactivity, and tobacco use, which significantly increase the risk of non-communicable diseases globally. Implantable drug delivery devices are increasingly being used to provide long-term, controlled medication administration for chronic conditions, improving patient compliance and treatment effectiveness. For example, in August 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that 90% of the nation’s $4.9 trillion in annual healthcare spending is attributed to individuals with chronic and mental health conditions. Furthermore, more than 84,000 Americans die each year from heart disease or stroke, with the costs associated with cardiovascular diseases projected to reach approximately $2 trillion by 2050. As a result, the growing incidence of chronic diseases is driving the demand for implantable drug delivery devices.
The increasing healthcare expenditure is expected to drive the growth of the implantable drug delivery devices market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare services, products, and public health activities within a country or system, covering areas such as hospital care, physician services, medicines, medical devices, long-term care, and preventive programs. As the burden of chronic diseases rises, there is an increasing need for continuous treatment, long-term medication, and frequent clinical visits, which significantly raises overall healthcare spending. The growing healthcare expenditure supports the implantable drug delivery devices market by facilitating the wider adoption of advanced, long-term treatment technologies. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported that between 2023 and 2024, overall healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. As a result, the growing healthcare expenditure is contributing to the expansion of the implantable drug delivery devices market.
In May 2024, Arecor, a UK-based biopharmaceutical company specializing in novel formulations, partnered with Medtronic to develop a highly concentrated yet stable liquid formulation of an undisclosed Medtronic therapeutic product. As part of this collaboration, Medtronic will fund the formulation and development of an Arestat-enabled insulin, specifically designed for implantable delivery. This partnership aims to enhance therapeutic precision and improve patient outcomes. Medtronic, a US-based health technology company, is focused on developing a high-concentration, thermostable insulin for use in next-generation implantable pumps.
Major companies operating in the implantable drug delivery devices market are AbbVie Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck & Co. Inc., Genentech Inc, EyePoint Pharmaceuticals Inc., DSM Biomedical, Delpor Inc., Teleflex Incorporated, Biotronik Inc., Alcon Inc., Terumo Corporation, Endologix Inc., Innocoll Biotherapeutics, Atossa Therapeutics Inc., Intersect ENT, Microchips Biotech, Theradaptive Inc., CollPlant, Intarcia Therapeutics, Glaukos Corporation.
North America was the largest region in the implantable drug delivery devices market in 2025. Asia-Pacific was the second-largest region in the implantable drug delivery devices market report. The regions covered in the implantable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable drug delivery devices market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the implantable drug delivery devices market by increasing costs of imported polymers, micro-pumps, electronic components, and precision manufacturing equipment used in implant fabrication. North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher production costs for export-oriented implants. These tariffs are elevating device prices and extending development timelines. At the same time, they are encouraging local manufacturing, regional material sourcing, and innovation in cost-efficient implantable drug delivery platforms.
The implantable drug delivery devices market research report is one of a series of new reports that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable drug delivery devices are specialized drug delivery systems that are surgically implanted beneath the skin. These devices release drugs from a reservoir directly into the bloodstream, enabling targeted drug delivery and reducing the need for larger doses, which, in turn, minimizes potential side effects.
The primary product categories within the domain of implantable drug delivery devices include contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and various other devices. Spinal implants, for instance, aid surgeons in treating deformities, providing spinal stability, and promoting fusion during surgical procedures. These devices employ a range of technologies, including diffusion, osmosis, magnetic mechanisms, and others. They find applications in a variety of medical fields, such as contraception, ophthalmology, cardiovascular treatments, diabetes management, oncology, the treatment of autoimmune diseases, and other medical areas.
The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The implantable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $33.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of smart implantable devices, rising demand for personalized drug delivery, expansion of biodegradable implant technologies, growing investments in combination drug-device products, increasing regulatory approvals for implantable therapies. Major trends in the forecast period include increasing adoption of controlled-release implant systems, rising use of bio-absorbable implant materials, growing demand for site-specific drug delivery, expansion of miniaturized implantable devices, enhanced focus on patient compliance.
The increasing incidence of chronic diseases is expected to drive the growth of the implantable drug delivery devices market in the coming years. Chronic diseases are long-lasting medical conditions that persist for extended periods, typically three months or more. The rise in chronic diseases is largely attributed to widespread unhealthy lifestyle habits, such as poor nutrition, physical inactivity, and tobacco use, which significantly increase the risk of non-communicable diseases globally. Implantable drug delivery devices are increasingly being used to provide long-term, controlled medication administration for chronic conditions, improving patient compliance and treatment effectiveness. For example, in August 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that 90% of the nation’s $4.9 trillion in annual healthcare spending is attributed to individuals with chronic and mental health conditions. Furthermore, more than 84,000 Americans die each year from heart disease or stroke, with the costs associated with cardiovascular diseases projected to reach approximately $2 trillion by 2050. As a result, the growing incidence of chronic diseases is driving the demand for implantable drug delivery devices.
The increasing healthcare expenditure is expected to drive the growth of the implantable drug delivery devices market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare services, products, and public health activities within a country or system, covering areas such as hospital care, physician services, medicines, medical devices, long-term care, and preventive programs. As the burden of chronic diseases rises, there is an increasing need for continuous treatment, long-term medication, and frequent clinical visits, which significantly raises overall healthcare spending. The growing healthcare expenditure supports the implantable drug delivery devices market by facilitating the wider adoption of advanced, long-term treatment technologies. For example, in April 2025, the Office for National Statistics, a UK-based government department, reported that between 2023 and 2024, overall healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms after adjusting for inflation. As a result, the growing healthcare expenditure is contributing to the expansion of the implantable drug delivery devices market.
In May 2024, Arecor, a UK-based biopharmaceutical company specializing in novel formulations, partnered with Medtronic to develop a highly concentrated yet stable liquid formulation of an undisclosed Medtronic therapeutic product. As part of this collaboration, Medtronic will fund the formulation and development of an Arestat-enabled insulin, specifically designed for implantable delivery. This partnership aims to enhance therapeutic precision and improve patient outcomes. Medtronic, a US-based health technology company, is focused on developing a high-concentration, thermostable insulin for use in next-generation implantable pumps.
Major companies operating in the implantable drug delivery devices market are AbbVie Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck & Co. Inc., Genentech Inc, EyePoint Pharmaceuticals Inc., DSM Biomedical, Delpor Inc., Teleflex Incorporated, Biotronik Inc., Alcon Inc., Terumo Corporation, Endologix Inc., Innocoll Biotherapeutics, Atossa Therapeutics Inc., Intersect ENT, Microchips Biotech, Theradaptive Inc., CollPlant, Intarcia Therapeutics, Glaukos Corporation.
North America was the largest region in the implantable drug delivery devices market in 2025. Asia-Pacific was the second-largest region in the implantable drug delivery devices market report. The regions covered in the implantable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable drug delivery devices market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the implantable drug delivery devices market by increasing costs of imported polymers, micro-pumps, electronic components, and precision manufacturing equipment used in implant fabrication. North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces higher production costs for export-oriented implants. These tariffs are elevating device prices and extending development timelines. At the same time, they are encouraging local manufacturing, regional material sourcing, and innovation in cost-efficient implantable drug delivery platforms.
The implantable drug delivery devices market research report is one of a series of new reports that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Implantable drug delivery devices are specialized drug delivery systems that are surgically implanted beneath the skin. These devices release drugs from a reservoir directly into the bloodstream, enabling targeted drug delivery and reducing the need for larger doses, which, in turn, minimizes potential side effects.
The primary product categories within the domain of implantable drug delivery devices include contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and various other devices. Spinal implants, for instance, aid surgeons in treating deformities, providing spinal stability, and promoting fusion during surgical procedures. These devices employ a range of technologies, including diffusion, osmosis, magnetic mechanisms, and others. They find applications in a variety of medical fields, such as contraception, ophthalmology, cardiovascular treatments, diabetes management, oncology, the treatment of autoimmune diseases, and other medical areas.
The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Implantable Drug Delivery Devices Market Characteristics
3. Implantable Drug Delivery Devices Market Supply Chain Analysis
4. Global Implantable Drug Delivery Devices Market Trends and Strategies
5. Implantable Drug Delivery Devices Market Analysis of End Use Industries
7. Global Implantable Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Implantable Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Implantable Drug Delivery Devices Market Segmentation
10. Implantable Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Implantable Drug Delivery Devices Market
12. China Implantable Drug Delivery Devices Market
13. India Implantable Drug Delivery Devices Market
14. Japan Implantable Drug Delivery Devices Market
15. Australia Implantable Drug Delivery Devices Market
16. Indonesia Implantable Drug Delivery Devices Market
17. South Korea Implantable Drug Delivery Devices Market
18. Bangladesh Implantable Drug Delivery Devices Market
19. Thailand Implantable Drug Delivery Devices Market
20. Vietnam Implantable Drug Delivery Devices Market
21. Malaysia Implantable Drug Delivery Devices Market
22. Singapore Implantable Drug Delivery Devices Market
23. Philippines Implantable Drug Delivery Devices Market
24. Hong Kong Implantable Drug Delivery Devices Market
25. New Zealand Implantable Drug Delivery Devices Market
26. Taiwan Implantable Drug Delivery Devices Market
27. South East Asia Implantable Drug Delivery Devices Market
28. Western Europe Implantable Drug Delivery Devices Market
29. UK Implantable Drug Delivery Devices Market
30. Germany Implantable Drug Delivery Devices Market
31. France Implantable Drug Delivery Devices Market
32. Italy Implantable Drug Delivery Devices Market
33. Spain Implantable Drug Delivery Devices Market
34. Austria Implantable Drug Delivery Devices Market
35. Belgium Implantable Drug Delivery Devices Market
36. Denmark Implantable Drug Delivery Devices Market
37. Finland Implantable Drug Delivery Devices Market
38. Ireland Implantable Drug Delivery Devices Market
39. Netherlands Implantable Drug Delivery Devices Market
40. Norway Implantable Drug Delivery Devices Market
41. Portugal Implantable Drug Delivery Devices Market
42. Sweden Implantable Drug Delivery Devices Market
42. Switzerland Implantable Drug Delivery Devices Market
43. Eastern Europe Implantable Drug Delivery Devices Market
44. Russia Implantable Drug Delivery Devices Market
45. Czech Republic Implantable Drug Delivery Devices Market
46. Poland Implantable Drug Delivery Devices Market
47. Romania Implantable Drug Delivery Devices Market
48. Ukraine Implantable Drug Delivery Devices Market
49. North America Implantable Drug Delivery Devices Market
50. USA Implantable Drug Delivery Devices Market
51. Canada Implantable Drug Delivery Devices Market
52. Mexico Implantable Drug Delivery Devices Market
53. South America Implantable Drug Delivery Devices Market
54. Brazil Implantable Drug Delivery Devices Market
55. Chile Implantable Drug Delivery Devices Market
56. Argentina Implantable Drug Delivery Devices Market
57. Colombia Implantable Drug Delivery Devices Market
58. Peru Implantable Drug Delivery Devices Market
59. Middle East Implantable Drug Delivery Devices Market
60. Saudi Arabia Implantable Drug Delivery Devices Market
61. Israel Implantable Drug Delivery Devices Market
62. Iran Implantable Drug Delivery Devices Market
63. Turkey Implantable Drug Delivery Devices Market
64. United Arab Emirates Implantable Drug Delivery Devices Market
65. Africa Implantable Drug Delivery Devices Market
66. Egypt Implantable Drug Delivery Devices Market
67. Nigeria Implantable Drug Delivery Devices Market
68. South Africa Implantable Drug Delivery Devices Market
70. Implantable Drug Delivery Devices Market Competitive Landscape and Company Profiles
71. Implantable Drug Delivery Devices Market Other Major and Innovative Companies
74. Implantable Drug Delivery Devices Market High Potential Countries, Segments and Strategies
75. Appendix
List of Tables
Executive Summary
Implantable Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses implantable drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for implantable drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Contraceptive Implants; Spinal Implants; Brachytherapy Seeds; Drug-Eluting Stents; Bio-absorbable Stents; Intraocular Stents; Infusion Pumps; Other Applications2) By Technology: Diffusion; Osmotic; Magnetic; Other Technologies
3) By Application: Contraception; Ophthalmology; Cardiovascular; Diabetes; Oncology; Autoimmune Diseases; Other Applications
Subsegments:
1) By Contraceptive Implants: Hormonal Contraceptive Implants; Non-hormonal Contraceptive Implants2) By Spinal Implants: Biodegradable Spinal Implants; Non-biodegradable Spinal Implants
3) By Brachytherapy Seeds: Iodine-125 Seeds; Palladium-103 Seeds; Cesium-131 Seeds; Other Brachytherapy Seeds
4) By Drug-Eluting Stents: Coronary Drug-Eluting Stents; Peripheral Drug-Eluting Stents
5) By Bio-absorbable Stents: Polymer-based Bio-absorbable Stents; Metal-based Bio-absorbable Stents
6) By Intraocular Stents: Glaucoma Intraocular Stents; Cataract Surgery Intraocular Stents
7) By Infusion Pumps: Insulin Pumps; Chemotherapy Infusion Pumps; Pain Management Infusion Pumps; Other Infusion Pumps
8) By Other Applications: Implantable Reservoirs; Implantable Micro-pumps; Implantable Drug Elution Devices
Companies Mentioned: AbbVie Inc.; Bayer HealthCare; Medtronic Inc.; Nucletron; Boston Scientific Corporation; Abbott Laboratories; Bausch and Lomb Inc.; Merck & Co. Inc.; Genentech Inc; EyePoint Pharmaceuticals Inc.; DSM Biomedical; Delpor Inc.; Teleflex Incorporated; Biotronik Inc.; Alcon Inc.; Terumo Corporation; Endologix Inc.; Innocoll Biotherapeutics; Atossa Therapeutics Inc.; Intersect ENT; Microchips Biotech; Theradaptive Inc.; CollPlant; Intarcia Therapeutics; Glaukos Corporation
Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Implantable Drug Delivery Devices market report include:- AbbVie Inc.
- Bayer HealthCare
- Medtronic Inc.
- Nucletron
- Boston Scientific Corporation
- Abbott Laboratories
- Bausch and Lomb Inc.
- Merck & Co. Inc.
- Genentech Inc
- EyePoint Pharmaceuticals Inc.
- DSM Biomedical
- Delpor Inc.
- Teleflex Incorporated
- Biotronik Inc.
- Alcon Inc.
- Terumo Corporation
- Endologix Inc.
- Innocoll Biotherapeutics
- Atossa Therapeutics Inc.
- Intersect ENT
- Microchips Biotech
- Theradaptive Inc.
- CollPlant
- Intarcia Therapeutics
- Glaukos Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 23.91 Billion |
| Forecasted Market Value ( USD | $ 33.39 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
